Natco Pharma disclosed on Monday that it will raise its proposed investment in U.S.-based eGenesis Inc. to $16.7 million, an $2.7 million bump from the $14 million previously announced.
The additional capital will flow through Natco Pharma Inc. and Natco Pharma USA LLC, with the former committing $13.7 million and the latter $3 million. The notes carry an 8% compounded annual interest rate and are slated to mature by October 31, 2026.
Including the $8 million Natco already invested in 2024, the company’s total stake in eGenesis climbs to $24.7 million. This marks a significant deepening of Natco’s partnership in a biotech venture that is still pre‑revenue.
eGenesis is pioneering the use of CRISPR‑edited pig organs for human transplantation. The firm recently performed the world’s first pig‑kidney transplant under the FDA’s Expanded Access pathway, and has two more such procedures underway. Its pipeline also targets acute liver failure and heart transplantation.
For Natco, the expanded investment aligns with a broader push toward next‑generation therapeutics that address critical unmet medical needs. The company’s filing noted that the partnership could position it at the forefront of a market projected to grow rapidly as organ shortages persist.
While Natco has not issued new quarterly guidance, the increased stake may be viewed as a bullish signal by investors eyeing the emerging gene‑editing and transplantation sectors. Market watchers will likely keep an eye on Natco’s next earnings release for further clarity on how this partnership might translate into revenue streams.